Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.

Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Chang SJ, Lee SS

The American journal of gastroenterology1 Mar 2005Cited by 83 (Europe PMC)

PMID15743362DOI10.1111/j.1572-0241.2005.41381.xPepBankPUB-15743362

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In cirrhotic patients, octreotide reduced HVPG by 44.5 +/- 17.8% from baseline at 1 min (p < 0.05).
In plain wordsIn cirrhotic patients, octreotide reduced portal pressure from baseline at 1 min.
Peptide
Octreotide
Outcome
DecreaseHVPG at 1 min
Study
n = 21
Comparator
Baseline
Outcome group
Blood pressure · Liver
Studied dose
100 microg bolus followed by 250 microg/h infusion · intravenousAs given in this study (human).
Measurements
Change in HVPG from baseline
−44.5%
octreotide, 1 min, +/- 17.8
P value vs baseline
< 0.05 P
octreotide, 1 min
Source sentences
Summary
Octreotide markedly decreased HVPG (-44.5 +/- 17.8%) and PVF (-30.6 +/- 13.6%) compared to the baseline at 1 min (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-two cirrhotic patients with a history of variceal bleeding were randomized to receive either octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h (n = 21), or terlipressin 2 mg intravenous bolus (n = 21).
Summary · context
Mean arterial pressure (MAP), heart rate (HR), hepatic venous pressure gradient (HVPG), and PVF, assessed by duplex Doppler ultrasonography, were measured before and at 1, 5, 10, 15, 20, and 25 min after the start of drug administration.
Report a problemFND-1574336201
02HumanNon-randomized trialEfficacy outcome
In cirrhotic patients, octreotide reduced PVF by 30.6 +/- 13.6% from baseline at 1 min (p < 0.05).
In plain wordsIn cirrhotic patients, octreotide reduced portal blood flow from baseline at 1 min.
Peptide
Octreotide
Outcome
DecreasePVF at 1 min
Study
n = 21
Comparator
Baseline
Outcome group
Vascular function · Liver
Studied dose
100 microg bolus followed by 250 microg/h infusion · intravenousAs given in this study (human).
Measurements
Change in PVF from baseline
−30.6%
octreotide, 1 min, +/- 13.6
P value vs baseline
< 0.05 P
octreotide, 1 min
Source sentences
Summary
Octreotide markedly decreased HVPG (-44.5 +/- 17.8%) and PVF (-30.6 +/- 13.6%) compared to the baseline at 1 min (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-two cirrhotic patients with a history of variceal bleeding were randomized to receive either octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h (n = 21), or terlipressin 2 mg intravenous bolus (n = 21).
Summary · context
Mean arterial pressure (MAP), heart rate (HR), hepatic venous pressure gradient (HVPG), and PVF, assessed by duplex Doppler ultrasonography, were measured before and at 1, 5, 10, 15, 20, and 25 min after the start of drug administration.
Report a problemFND-1574336202
03HumanNon-randomized trialEfficacy outcome
In cirrhotic patients, HVPG after octreotide was -7.1 +/- 28.9% from baseline at 5 min, without significant difference.
In plain wordsIn cirrhotic patients, portal pressure after octreotide did not differ significantly from baseline at 5 min.
Peptide
Octreotide
Outcome
No significant changeHVPG at 5 min
Study
n = 21
Comparator
Baseline
Outcome group
Blood pressure · Liver
Studied dose
100 microg bolus followed by 250 microg/h infusion · intravenousAs given in this study (human).
Measurements
Change in HVPG from baseline
−7.1%
octreotide, 5 min, +/- 28.9
Source sentences
Summary
Thereafter, both variables rapidly returned toward the baseline, and by 5 min, no significant differences in HVPG (-7.1 +/- 28.9%) and PVF (10.2 +/- 26.2%) were noted.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-two cirrhotic patients with a history of variceal bleeding were randomized to receive either octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h (n = 21), or terlipressin 2 mg intravenous bolus (n = 21).
Summary · context
Mean arterial pressure (MAP), heart rate (HR), hepatic venous pressure gradient (HVPG), and PVF, assessed by duplex Doppler ultrasonography, were measured before and at 1, 5, 10, 15, 20, and 25 min after the start of drug administration.
Report a problemFND-1574336203
04HumanNon-randomized trialEfficacy outcome
In cirrhotic patients, PVF after octreotide was 10.2 +/- 26.2% above baseline at 5 min, without significant difference.
In plain wordsIn cirrhotic patients, portal blood flow after octreotide did not differ significantly from baseline at 5 min.
Peptide
Octreotide
Outcome
No significant changePVF at 5 min
Study
n = 21
Comparator
Baseline
Outcome group
Vascular function · Liver
Studied dose
100 microg bolus followed by 250 microg/h infusion · intravenousAs given in this study (human).
Measurements
Change in PVF from baseline
10.2%
octreotide, 5 min, +/- 26.2
Source sentences
Summary
Thereafter, both variables rapidly returned toward the baseline, and by 5 min, no significant differences in HVPG (-7.1 +/- 28.9%) and PVF (10.2 +/- 26.2%) were noted.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-two cirrhotic patients with a history of variceal bleeding were randomized to receive either octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h (n = 21), or terlipressin 2 mg intravenous bolus (n = 21).
Summary · context
Mean arterial pressure (MAP), heart rate (HR), hepatic venous pressure gradient (HVPG), and PVF, assessed by duplex Doppler ultrasonography, were measured before and at 1, 5, 10, 15, 20, and 25 min after the start of drug administration.
Report a problemFND-1574336204
05HumanNon-randomized trialEfficacy outcome
In cirrhotic patients, octreotide had a transient effect on mean arterial pressure relative to baseline.
In plain wordsIn cirrhotic patients, octreotide changed arterial pressure transiently from baseline.
Peptide
Octreotide
Outcome
Direction not reportedMean arterial pressure
Study
n = 21
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
100 microg bolus followed by 250 microg/h infusion · intravenousAs given in this study (human).
Source sentences
Summary
A similar transient effect on MAP and HR was observed.
3 context sentences(design, population, supporting numbers)
Summary · context
Octreotide markedly decreased HVPG (-44.5 +/- 17.8%) and PVF (-30.6 +/- 13.6%) compared to the baseline at 1 min (p < 0.05). Thereafter, both variables rapidly returned toward the baseline, and by 5 min, no significant differences in HVPG (-7.1 +/- 28.9%) and PVF (10.2 +/- 26.2%) were noted.
Summary · context
Forty-two cirrhotic patients with a history of variceal bleeding were randomized to receive either octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h (n = 21), or terlipressin 2 mg intravenous bolus (n = 21).
Summary · context
Mean arterial pressure (MAP), heart rate (HR), hepatic venous pressure gradient (HVPG), and PVF, assessed by duplex Doppler ultrasonography, were measured before and at 1, 5, 10, 15, 20, and 25 min after the start of drug administration.
Report a problemFND-1574336205
06HumanNon-randomized trialEfficacy outcome
In cirrhotic patients, octreotide had a transient effect on heart rate relative to baseline.
In plain wordsIn cirrhotic patients, octreotide changed heart rate transiently from baseline.
Peptide
Octreotide
Outcome
Direction not reportedHeart rate
Study
n = 21
Comparator
Baseline
Outcome group
Heart function · Cardiovascular
Studied dose
100 microg bolus followed by 250 microg/h infusion · intravenousAs given in this study (human).
Source sentences
Summary
A similar transient effect on MAP and HR was observed.
3 context sentences(design, population, supporting numbers)
Summary · context
Octreotide markedly decreased HVPG (-44.5 +/- 17.8%) and PVF (-30.6 +/- 13.6%) compared to the baseline at 1 min (p < 0.05). Thereafter, both variables rapidly returned toward the baseline, and by 5 min, no significant differences in HVPG (-7.1 +/- 28.9%) and PVF (10.2 +/- 26.2%) were noted.
Summary · context
Forty-two cirrhotic patients with a history of variceal bleeding were randomized to receive either octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h (n = 21), or terlipressin 2 mg intravenous bolus (n = 21).
Summary · context
Mean arterial pressure (MAP), heart rate (HR), hepatic venous pressure gradient (HVPG), and PVF, assessed by duplex Doppler ultrasonography, were measured before and at 1, 5, 10, 15, 20, and 25 min after the start of drug administration.
Report a problemFND-1574336206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase not statedNCT02311608

Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails

Shanghai Zhongshan Hospitaln = 1,320Feb 2014 to est. Jun 2016

Liver Cirrhosis · Esophageal and Gastric Varices · Hemorrhage

Trial page ClinicalTrials.govUpdated 8 Dec 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.